Hospital zinc trial reports less COVID-19 progression
Progression to intensive care or death was less frequent with zinc, but recovery analyses gave mixed statistical results.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In hospitalized adults with COVID-19, the zinc group had less reported progression to intensive care or death than the standard-care group. Mean recovery time was shorter, but the time-to-recovery hazard analysis did not reach statistical significance. This offers preliminary treatment evidence in a hospital setting, without establishing a role for routine supplementation or prevention.
The reported enrollment total does not match the group counts. The trial was open-label and conducted at one center; the abstract also leaves the primary endpoint's assessment window unclear.
What researchers found
Disease progression: ICU admission or death
Zinc plus standard care versus standard care alone; assessment window not reported. The odds ratio is not a percentage reduction in risk.
Recovery results need both analyses
Recovery was analyzed in different ways. The average recovery-time difference was statistically significant, while the hazard-model result remained uncertain. These findings should be reported together rather than reduced to a single recovery claim.
Safety evidence remains limited
No adverse events were attributed to zinc in the trial. That describes this study's experience and does not establish broad safety, especially when the abstract provides limited enrollment and follow-up detail.
The original publication
Zinc adjuvant treatment in SARS-CoV-2: A randomized clinical trial.
Gómez-Zorrilla S, Sendra E, Du J et al.
J Trace Elem Med Biol · 2025
- PubMed ID
- 41076985
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.